2015
DOI: 10.1016/j.tibtech.2015.07.002
|View full text |Cite
|
Sign up to set email alerts
|

Closing regulatory gaps: new ground rules for platelet-rich plasma

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
39
0
3

Year Published

2017
2017
2024
2024

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations
Cited by 27 publications
(42 citation statements)
references
References 9 publications
0
39
0
3
Order By: Relevance
“…Unlike mice, full-excisional wound regeneration in humans is a more gradual and complex process that requires between months and years, depending on the wound characteristics 1 . Bearing this in mind, the acceleration of wound healing by PRP optimisation in patients could represent a reduction in hospitalisation costs, a decrease in analgesic and anti-inflammatory indications, and may lower risks of non-healing complications including infection, lost limb functionality, and amputation 39 , 40 , that are commonly associated with impaired skin healing and regeneration in diabetic chronic wounds and dermal burns, which are target diseases for PRP treatment.…”
Section: Discussionmentioning
confidence: 99%
“…Unlike mice, full-excisional wound regeneration in humans is a more gradual and complex process that requires between months and years, depending on the wound characteristics 1 . Bearing this in mind, the acceleration of wound healing by PRP optimisation in patients could represent a reduction in hospitalisation costs, a decrease in analgesic and anti-inflammatory indications, and may lower risks of non-healing complications including infection, lost limb functionality, and amputation 39 , 40 , that are commonly associated with impaired skin healing and regeneration in diabetic chronic wounds and dermal burns, which are target diseases for PRP treatment.…”
Section: Discussionmentioning
confidence: 99%
“… 10 , 11 A particular type of PRP is eye drop PRGF (plasma rich in growth factor) manufactured with the Endoret system (BTI Biotechnology Institute, S.L., Miñano, Álava, Spain). This eye drop has approval as a human use product, 12 and it is manufactured with a closed technique that makes its manufacture safer and more reproducible. It has a standardized manufacturing protocol; calcium chloride is used as a platelet activator, which initiates a greater release of growth factors, 13 , 14 and when the PRGF is heated at 56°C for 1 hour, the immunoglobulin E content and complement activity are reduced, and its stability can be maintained up to 6 months.…”
Section: Introductionmentioning
confidence: 99%
“…Of note, all of these procedures were performed using PRP anticoagulated with ACD and without calcium restoration arguing about a possible toxic effect caused by the anticoagulant. Unfortunately, and in contrast with the industrialized medical drugs that require pharmacovigilance, the heterogeneity of platelet-derived products hinders the establishment of regulatory frameworks worldwide required to apply a mandatory and unified record of side effects (Anitua et al, 2015;Beitzel et al, 2015). To count with more of these registers would allow a deeper understanding about the adverse effects of anticoagulants used in regenerative protocols mediated by platelets allowing providing therapeutic strategies to prevent and treat these complications.…”
Section: Discussionmentioning
confidence: 99%